Peritoneal carcinomatosis from ovarian cancer

Chemosensitivity test and tissue markers as predictors of response to chemotherapy

Chiara Arienti, Anna Tesei, Giorgio M. Verdecchia, Massimo Framarini, Salvatore Virzì, Antonio Grassi, Emanuela Scarpi, Livia Turci, Rosella Silvestrini, Dino Amadori, Wainer Zoli

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Platinum-based regimens are the treatments of choice in ovarian cancer, which remains the leading cause of death from gynecological malignancies in the Western world. The aim of the present study was to compare the advantages and limits of a conventional chemosensitivity test with those of new biomolecular markers in predicting response to platinum regimens in a series of patients with peritoneal carcinomatosis from ovarian cancer.Methods: Fresh surgical biopsy specimens were obtained from 30 patients with primary or recurrent peritoneal carcinomatosis from ovarian cancer. ERCC1, GSTP1, MGMT, XPD, and BRCA1 gene expression levels were determined by Real-Time RT-PCR. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient.Results: MGMT and XPD expression was directly and significantly related to resistance to platinum-containing treatment (p = 0.036 and p = 0.043, respectively). Significant predictivity in terms of sensitivity and resistance was observed for MGMT expression (75.0% and 72.5%, respectively; p = 0.03), while high predictivity of resistance (90.9%) but very low predictivity of sensitivity (37.5%) (p = 0.06) were observed for XPD. The best overall and significant predictivity was observed for chemosensitivity test results (85.7% sensitivity and 91.3% resistance; p = 0.0003).Conclusions: The in vitro assay showed a consistency with results observed in vivo in 27 out of the 30 patients analyzed. Sensitivity and resistance profiles of different drugs used in vivo would therefore seem to be better defined by the in vitro chemosensitivity test than by expression levels of markers.

Original languageEnglish
Article number94
JournalJournal of Translational Medicine
Volume9
Issue number1
DOIs
Publication statusPublished - Jun 20 2011

Fingerprint

Chemotherapy
Platinum
Ovarian Neoplasms
Tissue
Carcinoma
Drug Therapy
Biopsy
BRCA1 Gene
Gene expression
Pharmaceutical Preparations
Western World
Assays
Real-Time Polymerase Chain Reaction
Cause of Death
Gene Expression
Therapeutics
In Vitro Techniques
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Peritoneal carcinomatosis from ovarian cancer : Chemosensitivity test and tissue markers as predictors of response to chemotherapy. / Arienti, Chiara; Tesei, Anna; Verdecchia, Giorgio M.; Framarini, Massimo; Virzì, Salvatore; Grassi, Antonio; Scarpi, Emanuela; Turci, Livia; Silvestrini, Rosella; Amadori, Dino; Zoli, Wainer.

In: Journal of Translational Medicine, Vol. 9, No. 1, 94, 20.06.2011.

Research output: Contribution to journalArticle

Arienti, Chiara ; Tesei, Anna ; Verdecchia, Giorgio M. ; Framarini, Massimo ; Virzì, Salvatore ; Grassi, Antonio ; Scarpi, Emanuela ; Turci, Livia ; Silvestrini, Rosella ; Amadori, Dino ; Zoli, Wainer. / Peritoneal carcinomatosis from ovarian cancer : Chemosensitivity test and tissue markers as predictors of response to chemotherapy. In: Journal of Translational Medicine. 2011 ; Vol. 9, No. 1.
@article{fb04550a8d19492e9bd3219250d92ecc,
title = "Peritoneal carcinomatosis from ovarian cancer: Chemosensitivity test and tissue markers as predictors of response to chemotherapy",
abstract = "Background: Platinum-based regimens are the treatments of choice in ovarian cancer, which remains the leading cause of death from gynecological malignancies in the Western world. The aim of the present study was to compare the advantages and limits of a conventional chemosensitivity test with those of new biomolecular markers in predicting response to platinum regimens in a series of patients with peritoneal carcinomatosis from ovarian cancer.Methods: Fresh surgical biopsy specimens were obtained from 30 patients with primary or recurrent peritoneal carcinomatosis from ovarian cancer. ERCC1, GSTP1, MGMT, XPD, and BRCA1 gene expression levels were determined by Real-Time RT-PCR. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient.Results: MGMT and XPD expression was directly and significantly related to resistance to platinum-containing treatment (p = 0.036 and p = 0.043, respectively). Significant predictivity in terms of sensitivity and resistance was observed for MGMT expression (75.0{\%} and 72.5{\%}, respectively; p = 0.03), while high predictivity of resistance (90.9{\%}) but very low predictivity of sensitivity (37.5{\%}) (p = 0.06) were observed for XPD. The best overall and significant predictivity was observed for chemosensitivity test results (85.7{\%} sensitivity and 91.3{\%} resistance; p = 0.0003).Conclusions: The in vitro assay showed a consistency with results observed in vivo in 27 out of the 30 patients analyzed. Sensitivity and resistance profiles of different drugs used in vivo would therefore seem to be better defined by the in vitro chemosensitivity test than by expression levels of markers.",
author = "Chiara Arienti and Anna Tesei and Verdecchia, {Giorgio M.} and Massimo Framarini and Salvatore Virz{\`i} and Antonio Grassi and Emanuela Scarpi and Livia Turci and Rosella Silvestrini and Dino Amadori and Wainer Zoli",
year = "2011",
month = "6",
day = "20",
doi = "10.1186/1479-5876-9-94",
language = "English",
volume = "9",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Peritoneal carcinomatosis from ovarian cancer

T2 - Chemosensitivity test and tissue markers as predictors of response to chemotherapy

AU - Arienti, Chiara

AU - Tesei, Anna

AU - Verdecchia, Giorgio M.

AU - Framarini, Massimo

AU - Virzì, Salvatore

AU - Grassi, Antonio

AU - Scarpi, Emanuela

AU - Turci, Livia

AU - Silvestrini, Rosella

AU - Amadori, Dino

AU - Zoli, Wainer

PY - 2011/6/20

Y1 - 2011/6/20

N2 - Background: Platinum-based regimens are the treatments of choice in ovarian cancer, which remains the leading cause of death from gynecological malignancies in the Western world. The aim of the present study was to compare the advantages and limits of a conventional chemosensitivity test with those of new biomolecular markers in predicting response to platinum regimens in a series of patients with peritoneal carcinomatosis from ovarian cancer.Methods: Fresh surgical biopsy specimens were obtained from 30 patients with primary or recurrent peritoneal carcinomatosis from ovarian cancer. ERCC1, GSTP1, MGMT, XPD, and BRCA1 gene expression levels were determined by Real-Time RT-PCR. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient.Results: MGMT and XPD expression was directly and significantly related to resistance to platinum-containing treatment (p = 0.036 and p = 0.043, respectively). Significant predictivity in terms of sensitivity and resistance was observed for MGMT expression (75.0% and 72.5%, respectively; p = 0.03), while high predictivity of resistance (90.9%) but very low predictivity of sensitivity (37.5%) (p = 0.06) were observed for XPD. The best overall and significant predictivity was observed for chemosensitivity test results (85.7% sensitivity and 91.3% resistance; p = 0.0003).Conclusions: The in vitro assay showed a consistency with results observed in vivo in 27 out of the 30 patients analyzed. Sensitivity and resistance profiles of different drugs used in vivo would therefore seem to be better defined by the in vitro chemosensitivity test than by expression levels of markers.

AB - Background: Platinum-based regimens are the treatments of choice in ovarian cancer, which remains the leading cause of death from gynecological malignancies in the Western world. The aim of the present study was to compare the advantages and limits of a conventional chemosensitivity test with those of new biomolecular markers in predicting response to platinum regimens in a series of patients with peritoneal carcinomatosis from ovarian cancer.Methods: Fresh surgical biopsy specimens were obtained from 30 patients with primary or recurrent peritoneal carcinomatosis from ovarian cancer. ERCC1, GSTP1, MGMT, XPD, and BRCA1 gene expression levels were determined by Real-Time RT-PCR. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient.Results: MGMT and XPD expression was directly and significantly related to resistance to platinum-containing treatment (p = 0.036 and p = 0.043, respectively). Significant predictivity in terms of sensitivity and resistance was observed for MGMT expression (75.0% and 72.5%, respectively; p = 0.03), while high predictivity of resistance (90.9%) but very low predictivity of sensitivity (37.5%) (p = 0.06) were observed for XPD. The best overall and significant predictivity was observed for chemosensitivity test results (85.7% sensitivity and 91.3% resistance; p = 0.0003).Conclusions: The in vitro assay showed a consistency with results observed in vivo in 27 out of the 30 patients analyzed. Sensitivity and resistance profiles of different drugs used in vivo would therefore seem to be better defined by the in vitro chemosensitivity test than by expression levels of markers.

UR - http://www.scopus.com/inward/record.url?scp=79959196985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959196985&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-9-94

DO - 10.1186/1479-5876-9-94

M3 - Article

VL - 9

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 94

ER -